Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214103) titled 'Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: University Hospital, Strasbourg, France
Condition:
Septic Shock
Coagulopathy
Intervention:
Drug: * Sivelestat intravenous infusion
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 1, 2026
Target Sample Size: ...